Independence Blue Cross (Independence) published new medical policies on July 1, 2022, to further communicate its coverage position on the drug aducanumab (Aduhelm) for the treatment of Alzheimer disease for its Commercial and Medicare Advantage members.
Effective June 7, 2021, the use of Aduhelm is considered experimental/investigational and therefore not covered for all indications, including the treatment of Alzheimer disease, for Independence Commercial members.
Effective April 7, 2022, and in accordance with Medicare, monoclonal antibodies directed against amyloid (including Aduhelm) for the treatment of Alzheimer disease is considered experimental/investigational and therefore not covered, except for Coverage with Evidence Development, for Independence Medicare Advantage members.
For more information, please view the following Independence medical policies: